Smartphone-delivered cognitive behavioral therapy for subthreshold depression with physical comorbidities: Evidence from the RESiLIENT trial.

J Affect DisordMay 20, 2026 (epub)
Clinical ResearchPsychiatry

Beibei Cui, Yan Luo, Aran Tajika et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial analyzed the effectiveness of smartphone-delivered cognitive behavioral therapy (CBT) for subthreshold depression in 3577 participants, including those with physical comorbidities. All CBT interventions significantly improved depression scores at week 6, with behavioral activation combined with problem solving showing the largest effects. By week 26, benefits were maintained across all groups.

Key findings

  • Behavioral activation combined with problem solving showed the largest effect in the no comorbidity group with a mean difference of -1.74.
  • In the current comorbidity group, the mean difference was -1.94 for the same intervention.
  • By week 26, benefits of BA combined with cognitive restructuring were maintained across all comorbidity groups.
  • Latent class analysis identified five multimorbidity classes impacting outcomes.

Why it matters

The findings suggest that smartphone-delivered CBT can effectively address depressive symptoms in patients with subthreshold depression, including those with physical comorbidities, highlighting its potential as a scalable mental health intervention.

Source

PubMed · PMID 42155856

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.